This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Marinus Pharmaceuticals’s 8K filing here.
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
Featured Articles
- Five stocks we like better than Marinus Pharmaceuticals
- 3 Warren Buffett Stocks to Buy Now
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- How to Use High Beta Stocks to Maximize Your Investing Profits
- MarketBeat Week in Review – 10/21- 10/25
